Betrixaban represents the first oral and long-lasting treatment to prevent deep vein thrombosis and pulmonary embolisms in acutely ill nonsurgical patients. The once-daily pill may be used in both hospital and home settings.
In the hospital setting, the drug will compete with the widely-used blood thinner, heparin, and Sanofi’s Lovenox. Analysts project Betrixaban will generate $313 million in sales by 2020, according to Thomson Reuters data.
More articles on supply chain:
Viewpoint: 4 insights into postapproval monitoring of medical devices
6 drugmakers in the headlines
Philips acquires noninvasive neurodiagnostics company for $36M
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.